https://www.regulatoryrapporteur.org/every-patient-has-a-story-to-tell-us/192.article 2024-02-14T14:43:36.753Z https://www.regulatoryrapporteur.org/main-navigation/an-integrated-approach-to-collecting-patient-experience-data-an-industry-perspective/193.article 2024-02-14T14:43:36.753Z https://www.regulatoryrapporteur.org/regulatory-procedures/the-application-of-patient-preference-information/194.article 2024-02-14T14:43:36.753Z https://www.regulatoryrapporteur.org/pharmaceuticals/considerations-for-sponsors-when-producing-an-eu-impd-impact-of-the-eu-ctr/195.article 2024-02-14T14:43:36.753Z https://www.regulatoryrapporteur.org/quality-partnering-rather-than-policing/196.article 2026-03-10T12:50:38.043Z https://www.regulatoryrapporteur.org/regulatory-procedures/european-regulatory-fees-complexity-concerns-and-solutions-for-efficiency/197.article 2024-02-14T14:43:36.753Z https://www.regulatoryrapporteur.org/case-study-the-evolving-regulatory-environment/198.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/editorials/patient-evidence-and-engagement/190.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/science-is-more-than-a-body-of-knowledge/191.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/medical-devices/successful-transition-of-your-iso-13485-qms-from-mdd/ivdd-to-mdr/ivdr/201.article 2024-02-14T14:44:05.950Z https://www.regulatoryrapporteur.org/quality-management-systems-applying-good-distribution-practices-to-the-biopharmaceutical-supply-chain/202.article 2024-02-14T14:44:05.950Z https://www.regulatoryrapporteur.org/pharmaceuticals/patient-information-why-do-things-go-wrong/203.article 2024-02-14T14:44:05.950Z https://www.regulatoryrapporteur.org/pharmaceuticals/a-view-ofthe-environmental-impact-of-pharmaceuticals/204.article 2024-02-14T14:44:05.950Z https://www.regulatoryrapporteur.org/medical-devices/ivds-and-medical-devices-post-market-surveillance-and-clinical-follow-up-requirements/207.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/medical-devices/regulation-versus-innovation-in-life-sciences/209.article 2024-02-14T14:44:05.950Z https://www.regulatoryrapporteur.org/editorials/the-need-for-robust-quality-management/210.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/pharmaceuticals/accelerated-regulatory-pathways-vaccines-for-tropical-diseases/206.article 2025-04-02T15:32:45.610Z https://www.regulatoryrapporteur.org/main-navigation/february-2023-contents/353.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/medical-devices/understanding-key-components-of-a-clinical-evaluation/225.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/medical-devices/imdrf-origins-purpose-and-current-work/223.article 2024-02-14T14:44:34.157Z https://www.regulatoryrapporteur.org/pharmaceuticals/environmental-impact-of-pharmaceuticals-and-regulation-in-the-eu/224.article 2024-02-14T14:44:34.157Z https://www.regulatoryrapporteur.org/emas-idmp-spor-implementation-guideline-v211/228.article 2024-02-14T14:44:34.157Z https://www.regulatoryrapporteur.org/is-consulting-in-regulatory-affairs-your-next-career-path/230.article 2024-02-14T14:44:34.157Z https://www.regulatoryrapporteur.org/editorials/setting-the-right-standards/227.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/direct-healthcare-professional-communication-as-an-intervention-tool-retrospective-analysis/231.article 2024-02-14T14:44:34.157Z https://www.regulatoryrapporteur.org/main-navigation/march-2023-contents/352.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/commentary/part-1-an-introduction-to-medicinal-cannabis/253.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/commentary/part-2-regulatory-background-of-medicinal-cannabis-in-eu-and-uk/254.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/commentary/part-3-the-medical-applications-of-cannabis/255.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/commentary/part-4-uk-routes-to-registration-for-medicinal-cannabis/256.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/contents-april-2023/350.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/interviews/patients-are-at-the-centre-of-everything/243.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/editorials/the-region-walking-the-regulatory-walk/244.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/contraceptive-product-registration-regional-harmonisation-through-the-east-african-community-mechanism/246.article 2024-02-14T14:46:57.717Z https://www.regulatoryrapporteur.org/the-transition-period-of-the-new-api-framework-in-brazil-is-coming-to-an-end/247.article 2024-02-14T14:46:57.717Z https://www.regulatoryrapporteur.org/pharmaceuticals/registration-and-post-approval-variation-of-pharmaceutical-drugs-in-latin-america-challenges-and-opportunities/249.article 2024-02-14T14:46:57.717Z https://www.regulatoryrapporteur.org/pharmaceuticals/an-overview-of-the-regulatory-framework-for-advanced-therapies/252.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/does-sole-dependence-on-reliance-models-contribute-to-a-sustainable-healthcare-ecosystem/250.article 2024-02-14T14:46:57.717Z https://www.regulatoryrapporteur.org/faqs 2024-07-01T14:24:45.510Z https://www.regulatoryrapporteur.org/industry-news/ghana-approves-r21-malaria-vaccine-first-to-exceed-whos-efficacy-target/234.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-cell-therapy-research-evaluates-immune-stimulant-cancer-therapies/257.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/moderna-secures-agreement-for-mrna-facility-in-kenya/258.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/duchenne-muscular-dystrophy-research-receives-ema-support/259.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/fda-approved-drug-shows-promising-results-for-itching-condition/260.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/how-ai-can-find-your-best-drug-match/262.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod-april-2023/263.article 2024-05-14T15:44:00.037Z https://www.regulatoryrapporteur.org/industry-news/eu-seeks-to-boost-innovation-ahead-of-future-pandemics/265.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/india-backs-ambitious-expansion-in-spending-to-support-medical-devices/271.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-reappoints-two-non-exec-directors/273.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/who-says-covid-19-no-longer-a-global-health-emergency/275.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/fda-approves-worlds-first-rsv-vaccine-for-use-in-over-60s/280.article 2023-05-21T14:26:34.097Z https://www.regulatoryrapporteur.org/industry-news/first-anaemia-drug-for-cats-given-expanded-conditional-approval/281.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/fda-licence-for-first-drug-to-treat-agitation-in-alzheimers/283.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/changing-of-the-guard-at-regulatory-rapporteur/286.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/pharmaceuticals/regulatory-guidelines-for-nutraceuticals-in-india/284.article 2024-02-14T14:47:48.933Z https://www.regulatoryrapporteur.org/pharmaceuticals/ensuring-promotional-materials-compliance-in-the-eu/285.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/editorials/mind-the-gap-innovation-vs-regulation-of-atmps/288.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/pharmaceuticals/alternatives-to-animal-testing-in-the-development-of-atmps/289.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/pharmaceuticals/g-e-t-ting-there-how-gene-editing-technologies-could-change-more-than-genes/276.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/pharmaceuticals/evolution-of-gmo-requirements-for-innovative-investigational-medicinal-products-upon-transition-to-the-eu-ctr/274.article 2025-06-18T09:25:50.640Z https://www.regulatoryrapporteur.org/industry-news/novel-gene-editing-method-roughly-threefold-better/292.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/contents-may-2023/293.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/industry-news/hiv-prevention-drug-is-first-to-be-made-in-south-africa/295.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/gene-therapy-gives-hope-to-patients-with-butterfly-skin/297.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/illegal-vapes-found-to-contain-lead-and-nickel-topra-fellow/298.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regulating-vaxzevria/294.article 2024-05-14T15:44:00.037Z https://www.regulatoryrapporteur.org/podcasts/regrappod-may-2023/299.article 2024-05-14T15:44:00.037Z https://www.regulatoryrapporteur.org/industry-news/mhra-seals-deal-for-fast-international-recognition-routes/306.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-plans-medical-device-technologies-streamlined-pathway/307.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/nice-recommends-its-first-ever-oral-migraine-treatment/308.article 2025-01-22T15:53:39.140Z https://www.regulatoryrapporteur.org/industry-news/neuralink-gets-fda-approval-for-its-first-brain-device-trials/311.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/ai-enabled-imaging-cuts-serious-stroke-diagnosis-times/313.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/umbrella-eu-us-vetmed-mra-comes-one-step-closer/315.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/implementation-of-regulation-eu-no-536/2014-a-cro-perspective/325.article 2024-02-14T14:48:42.623Z https://www.regulatoryrapporteur.org/main-navigation/a-critical-review-and-comparison-of-the-processes-when-seeking-scientific-advice-in-the-eu-and-the-usa-part-1/326.article 2024-02-14T14:48:42.623Z https://www.regulatoryrapporteur.org/main-navigation/decentralised-clinical-trials-a-european-union-recommendation-paper/327.article 2024-02-14T14:48:42.623Z https://www.regulatoryrapporteur.org/main-navigation/first-experiences-with-the-clinical-trial-regulation-a-company-perspective/328.article 2024-02-14T14:48:42.623Z https://www.regulatoryrapporteur.org/veterinary/reappraisal-of-regulation-of-agricultural-and-veterinary-chemicals-in-australia/329.article 2024-02-14T14:48:42.623Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-june-2023/330.article 2024-02-24T14:47:25.657Z https://www.regulatoryrapporteur.org/editorials/clinical-trials-ethical-ecological-and-economic-change/331.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/main-navigation/june-2023-contents/332.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/industry-news/uk-and-ireland-vetmed-product-label-guidance/334.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/change-across-the-medical-device-landscape/335.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/disposable-vapes-fda-cracks-down-on-illegal-sales/336.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/nhs-to-receive-21-million-fund-for-ai-diagnostics/337.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/fda-issues-guidance-for-clinical-trials-of-psychedelic-drugs/338.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/two-paediatric-type-2-diabetes-oral-drugs-receive-fda-approval/339.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/stakeholder-feedback-sought-on-ema-draft-clinical-guidelines/340.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/ai-generated-drug-first-to-reach-phase-ii-trials/341.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/australia-moves-to-permit-therapeutic-use-of-psychedelics/342.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/ai-brings-control-of-gene-expression-to-crispr-tech/343.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/wearables-can-spot-parkinsons-up-to-seven-years-earlier/351.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/wellcome-grants-57-million-to-combat-mrsa/354.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/mhra-corporate-plan-supports-access-for-patients-to-innovation/355.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/fda-approves-radical-design-of-pacemaker-with-no-leads/357.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/dementia-patients-retain-ability-to-learn-using-devices-study/358.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/january-2023-contents/359.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/industry-news/european-parliament-gives-first-stage-approval-for-revised-ema-fees-/360.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/good-safety-profile-of-covid-19-vaccines-declared-by-icmra/361.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/fda-approves-its-first-nonprescription-birth-control-pill/362.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/podcasts/regrappod-june-2023/356.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/fdas-emerging-technology-programme/363.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/december-2022-contents/375.article 2024-12-06T12:04:33.433Z https://www.regulatoryrapporteur.org/july/august-2023-contents/376.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/off-label-prescription-of-diabetes-drug-causes-shortage/378.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/pharmaceuticals/a-critical-review-and-comparison-of-the-processes-when-seeking-scientific-advice-in-the-eu-and-the-usa-part-2/373.article 2024-02-14T14:51:51.040Z https://www.regulatoryrapporteur.org/medical-devices/impact-of-clinical-data-requirements-following-eu-mdr-2017/745-and-clinical-evaluation-guidance-meddev-27/1-rev-4/374.article 2024-02-14T14:51:51.040Z https://www.regulatoryrapporteur.org/editorials/equal-access-to-medicines-finding-the-balance/379.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/african-medicines-agency-and-a-new-african-regulatory-ecosystem/364.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/eu-versus-rest-of-the-world-regulatory-frameworks-and-requirements-for-human-tissue-based-products/365.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/a-year-of-clinical-trials-under-ivdr-a-sponsors-perspective/367.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/regulatory-challenges-and-opportunities-facing-hearing-aid-manufacturers-in-europe/368.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/patient-groups-get-pharma-funding-often-petition-nice/387.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/safe-use-of-ai-is-subject-of-ema-reflection-paper/388.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/rapid-covid-19-breath-test-device-shows-promise/389.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/devices-sold-on-second-hand-market-retain-sensitive-data/390.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/human-covid-drug-set-to-treat-fcov-23-coronavirus-in-cats/394.article 2024-05-22T15:24:02.807Z https://www.regulatoryrapporteur.org/global-life-sciences-consultancy-created-from-ssi/nda-merger/400.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--july/august-2023/398.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/burkina-faso-gives-r21-malaria-vaccine-approval-in-children/401.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/semaglutide-may-help-with-pcos-and-addiction-disorders/402.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/biosimilars-cmc-development-considerations-from-the-sponsor-perspective/403.article 2024-02-14T14:52:20.187Z https://www.regulatoryrapporteur.org/warning-letters-for-direct-to-consumer-advertising-a-five-year-retrospective-analysis/405.article 2024-02-14T14:52:20.187Z https://www.regulatoryrapporteur.org/navigating-the-global-supply-of-starting-materials-for-cell-based-therapies/406.article 2024-02-14T14:52:20.187Z https://www.regulatoryrapporteur.org/september-2023-contents/407.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/regulatory-considerations-of-a-growing-pharmaceutical-company-a-uk/us-comparison-of-the-generics-industry/408.article 2024-02-14T14:52:20.187Z https://www.regulatoryrapporteur.org/editorials/the-worldwide-web-of-regulation/409.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/qanda-navigating-the-pharmaceutical-supply-chain/399.article 2024-02-14T14:52:20.187Z https://www.regulatoryrapporteur.org/mhra-publishes-recognition-route-revised-guidance/413.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/uk-doubles-capacity-for-certification-of-medical-devices/414.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/covid-19-vaccines-not-to-be-offered-routinely-to-healthy-under-65s/393.article 2024-05-22T15:00:54.137Z https://www.regulatoryrapporteur.org/industry-news/ema-future-vetmeds-for-healthy-animals-and-humans-seminar/416.article 2025-11-25T14:54:09.703Z https://www.regulatoryrapporteur.org/industry-news/fda-committee-finds-otc-decongestants-to-be-ineffective/429.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/nice-approves-use-of-rimegepant-in-nhs-to-treat-acute-migraine/430.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/nice-recommends-ai-to-aid-radiotherapy-treatment-in-england/431.article 2025-12-02T14:49:49.947Z https://www.regulatoryrapporteur.org/industry-news/ema-proposes-novel-method-to-assess-ckd-therapy-efficacy/432.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--september-2023/433.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/south-africa-set-to-investigate-jandj-over-mdr-tb-drug-pricing/436.article 2025-04-09T10:06:34.957Z https://www.regulatoryrapporteur.org/transition-to-the-new-qrd-template-for-veterinary-medicines-challenges-and-opportunities/434.article 2024-02-14T14:55:38.327Z https://www.regulatoryrapporteur.org/veterinary/autogenous-vaccines-under-regulation-eu-2019/6/435.article 2024-02-14T14:55:38.327Z https://www.regulatoryrapporteur.org/prequalification-of-veterinary-vaccines-and-medicines/437.article 2024-02-14T14:55:38.327Z https://www.regulatoryrapporteur.org/ema-activities-related-to-antiparasitic-veterinary-medicinal-products/438.article 2024-02-14T14:55:38.327Z https://www.regulatoryrapporteur.org/october-2023-contents/441.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/editorials/veterinary-medicines-the-challenges-of-new-regulation/442.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-devices/optimal-materials-selection-in-medical-device-development-a-proactive-biocompatibility-approach/444.article 2024-02-14T14:55:38.327Z https://www.regulatoryrapporteur.org/november-2023-contents/449.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/fda-to-establish-digital-health-advisory-committee/453.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-seeks-to-cut-approval-time-by-50-for-lowest-risk-rcts/454.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/patients-warned-about-falsified-ozempic-medication/455.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/industry-news/sars-cov-2-can-cause-brain-damage-in-dogs-says-study/456.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/who-endorses-use-of-r21/matrix-m-malaria-vaccine-in-children/457.article 2025-04-09T10:46:38.473Z https://www.regulatoryrapporteur.org/interviews/a-harmonised-approach-to-clinical-data-standards/448.article 2024-04-24T15:33:59.737Z https://www.regulatoryrapporteur.org/pharmaceuticals/overview-of-importation-strategy-from-an-fda-perspective-plair-vs-ftz/445.article 2024-02-14T14:56:07.173Z https://www.regulatoryrapporteur.org/pharmaceuticals/transitioning-from-paper-to-electronic-ifu-for-eu-mdr-2017/745/446.article 2024-02-14T14:56:07.173Z https://www.regulatoryrapporteur.org/pharmaceuticals/access-consortium-in-the-current-submission-transmission-ecosystem/447.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/pharmaceuticals/controlled-substances-development-past-present-and-future/459.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/editorials/editorial-november-2023/460.article 2024-04-30T14:56:04.090Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-november-2023/461.article 2024-02-24T14:47:12.120Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm4-the-evolving-clinical-trial-landscape/467.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/industry-news/icmra-regulators-to-mark-its-10th-year-at-event-in-australia-/472.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/cyber-risk-standard-gets-fda-backing-for-medical-devices/473.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/jandj-to-submit-trial-application-for-surgical-robot/477.article 2024-01-15T11:36:24.260Z https://www.regulatoryrapporteur.org/industry-news/researchers-aim-to-diagnose-alzheimers-through-blood-test/479.article 2023-11-14T16:44:24.520Z https://www.regulatoryrapporteur.org/industry-news/crispr-tool-used-to-treat-sickle-cell-and--thalassemia/485.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/australian-pm-makes-thalidomide-apology-on-62nd-anniversary/498.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-eligibility-checker-launched-for-irp-framework/499.article 2023-12-14T08:58:18.797Z https://www.regulatoryrapporteur.org/industry-news/probiotic-can-boost-immunity-in-children-study-findings-show/500.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/first-three-countries-added-to-who-listed-regulatory-agencies/501.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm1-update-on-eu-new-regulatory-legislation--ema-industry-and-others/464.article 2024-11-01T16:40:15.757Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm2-improving-the-odds-of-regulatory-success/465.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm3-a-spotlight-onto-the-future-fireside-chat/466.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm6-real-world-evidence-and-the-use-of-big-data-for-regulatory-decision-making-darwin-eu/470.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm7-paediatric-investigational-plans/474.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm8-regulatory-mechanisms-to-expedite-drug-development-and-patient-access-eg-prime/475.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm9-patient-engagement-in-the-regulatory-lifecycle-of-medicines/476.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/veterinary/vm1-horizontal-legislation-and-veterinary-medicine-availability/478.article 2024-11-01T16:43:12.650Z https://www.regulatoryrapporteur.org/veterinary/vm2-new-initiatives-in-regulatory-science/480.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/veterinary/vm3-regulatory-exchange-and-new/future-approaches/481.article 2024-04-05T08:00:26.380Z https://www.regulatoryrapporteur.org/veterinary/vm4-living-with-post-authorisation-obligations-progress-challenges-and-future-opportunities/483.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/december-2023-contents/487.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/veterinary/vm5-digital-innovation-to-support-animal-health/488.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/medical-devices/ivd3-ivdr-current-state/491.article 2025-11-11T16:08:51.320Z https://www.regulatoryrapporteur.org/medical-devices/ivd4-how-to-manage-diverging-regulatory-strategies-within-a-global-market-china-us-and-the-eu/492.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/medical-devices/md4-challenges-and-opportunities-for-small-companies-and-start-ups/493.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/main-navigation/ivd5-class-d-ivds/494.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/medical-devices/md5-post-market-challenges/495.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/ps1-health-technology-assessment-the-new-eu-regulation/496.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/pharmaceuticals/ps2-atmp-innovations-and-clinical-trials-with-genetically-modified-organisms/497.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/symposium-2023/topra-annual-lecture/502.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/editorials/advancing-global-healthcare-together/504.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm5/md1/ivd1-process-for-regulations-and-implications-of-different-legislation-how-to-follow-and-decide-which-regulation-will-impact-your-product-development/468.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/medical-devices/md2/ivd2-medical-technologies--a-catalyst-for-regulatory-innovations/489.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/medical-devices/md3-navigating-the-regulatory-maze-challenges-of-medical-device-software/490.article 2024-02-14T14:56:58.057Z https://www.regulatoryrapporteur.org/podcasts/regrappod--october-2023/509.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/us-could-seize-drug-patents-with-unused-reagon-era-law/508.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--november-2023/510.article 2025-01-27T10:39:35.547Z